Statistics Notes: Concealing treatment allocation in randomised trials
Top Cited Papers
- 25 August 2001
- Vol. 323 (7310) , 446-447
- https://doi.org/10.1136/bmj.323.7310.446
Abstract
We have previously explained why random allocation of treatments is a required design feature of controlled trials1 and explained how to generate a random allocation sequence.2 Here we consider the importance of concealing the treatment allocation until the patient is entered into the trial. Regardless of how the allocation sequence has been generated — such as by simple or stratified randomisation2 — there will be a prespecified sequence of treatment allocations. In principle, therefore, it is possible to know what treatment the next patient will get at the time when a decision is taken to consider the patient for entry into the trial. The strength of the randomised trial is based on aspects of design which eliminate various types of bias. Randomisation of patients to treatment groups eliminates bias by making the characteristics of the patients in two (or more) groups the same on average, and stratification with blocking may help to reduce chance imbalance in a particular trial.2 All this good work can be undone if a poor procedure is adopted to …Keywords
This publication has 12 references indexed in Scilit:
- Statistics Notes: Blinding in clinical trials and other studiesBMJ, 2000
- Statistics notes: How to randomiseBMJ, 1999
- Statistics notes: Treatment allocation in controlled trials: why randomise?BMJ, 1999
- Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?Published by Elsevier ,1998
- Improving the Quality of Reporting of Randomized Controlled TrialsJAMA, 1996
- Improving the quality of reporting of randomized controlled trials. The CONSORT statementJAMA, 1996
- Subverting Randomization in Controlled TrialsJAMA, 1995
- Empirical Evidence of BiasJAMA, 1995
- Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trialsJAMA, 1995
- Streptomycin Treatment of Pulmonary Tuberculosis: A Medical Research Council InvestigationBMJ, 1948